Latest Headlines

31. Leica Biosystems And CellCarta Expand Collaborative Companion Diagnostic Development Model To Accelerate Commercialization Globally 5/29/2026

    CellCarta, a leading global precision medicine laboratory services provider and Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced a strategic partnership to bring a proven companion diagnostic (CDx) joint development model from China to biopharma sponsors globally.

32. DELFI Diagnostics Receives New York State Department Of Health Clinical Laboratory Permit, Completing Authorization To Serve Health Systems Across All 50 States 5/28/2026

    DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory Permit and Test Approval letter from the New York State Department of Health (NYSDOH). With this permit, DELFI is now authorized to offer its FirstLook™ Lung laboratory-developed test (LDT) in New York.

33. Illumina And SPT Labtech Unveil fireflyGO, Enabling Faster, Simpler Targeted Oncology Research 5/28/2026

    Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research.

34. Sysmex America Introduces Next Generation XR-Series™ Hematology Solution For Clinical Laboratories 5/28/2026

    Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has introduced the next generation XR-Series, a hematology solution designed to help busy laboratories deliver fast, reliable results while maintaining efficient workflows.

35. 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected By State Of Vermont To Screen Up To 4,500 Firefighters 5/27/2026

    20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood (“MCED”) test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services (“NDS”).

36. CellCarta And Sonic Healthcare Establish Strategic Partnership To Commercialize Companion Diagnostics Through Lab Network 5/27/2026

    CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a Strategic Partnership with Sonic Healthcare USA, Inc. ("SHUAS" or "Sonic") to launch the first commercial laboratory relationship in CellCarta's Lab Network strategy, designed to support commercialization of companion diagnostics developed through CellCarta's single-site PMA CDx bridging model.

37. American Cancer Society Recommends Guardant Health's Shield Blood Test In Updated Colorectal Cancer Screening Guidelines 5/27/2026

    Guardant Health, Inc. a leading precision oncology company, announced that its FDA-approved Shield blood test is now included in updated American Cancer Society (ACS) Colorectal Cancer (CRC) Screening Guidelines published today.

38. CPC Biotech Collaborates With Multiply Labs To Advance Cell Therapy Automation 5/27/2026

    CPC Biotech, part of PSG and Dover (NYSE: DOV) and a leading manufacturer of connectors, pumps, and flow sensors used in biopharmaceutical processing, has collaborated with Multiply Labs to rapidly advance the use of robotic systems in cell therapy manufacturing.

39. FDA Breakthrough Device Designation Marks Major Milestone For Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test 5/27/2026

    Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals.

40. Argonne Launches First Large-Scale AI Inference Service For Open Science 5/27/2026

    The U.S. Department of Energy’s (DOE) Argonne National Laboratory has launched a first-of-its-kind AI inference service to help researchers across the nation accelerate discovery and innovation.